NASDAQ:NVIV - Invivo Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.69 +0.03 (+1.81 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.69
Today's Range$1.61 - $1.70
52-Week Range$1.34 - $15.50
Volume39,262 shs
Average Volume83,019 shs
Market Capitalization$15.73 million
P/E Ratio-0.09
Dividend YieldN/A
Beta1.71
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.37 per share

Profitability

Net Income$-26,740,000.00

Miscellaneous

EmployeesN/A
Market Cap$15.73 million
Next Earnings Date3/25/2019 (Estimated)
OptionableNot Optionable

Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Invivo Therapeutics shares reverse split before market open on Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) released its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($7.48) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $7.07. View Invivo Therapeutics' Earnings History.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for Invivo Therapeutics.

Has Invivo Therapeutics been receiving favorable news coverage?

News coverage about NVIV stock has been trending somewhat negative on Saturday, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Invivo Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Who are some of Invivo Therapeutics' key competitors?

What other stocks do shareholders of Invivo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Celgene (CELG), Flexion Therapeutics (FLXN), Ophthotech (OPHT), Verastem (VSTM), iShares US Preferred Stock ETF (PFF), Global Blood Therapeutics (GBT), Novavax (NVAX) and Exelixis (EXEL).

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the folowing people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
  • Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
  • Mr. William D'Agostino PE, Sr. VP of Operations

Who are Invivo Therapeutics' major shareholders?

Invivo Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include CVI Holdings LLC (1.98%). View Institutional Ownership Trends for Invivo Therapeutics.

Which major investors are buying Invivo Therapeutics stock?

NVIV stock was bought by a variety of institutional investors in the last quarter, including CVI Holdings LLC. View Insider Buying and Selling for Invivo Therapeutics.

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $1.69.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $15.73 million. The biotechnology company earns $-26,740,000.00 in net income (profit) each year or ($18.50) on an earnings per share basis.

What is Invivo Therapeutics' official website?

The official website for Invivo Therapeutics is http://www.invivotherapeutics.com.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  278
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel